Plus Therapeutics (PSTV) Institutional Ownership $0.67 +0.02 (+3.18%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Plus Therapeutics (NASDAQ:PSTV)CurrentInstitutional OwnershipPercentage3.28%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$835.96KNumber ofInstitutional Sellers(last 12 months)0 Get PSTV Insider Trade Alerts Want to know when executives and insiders are buying or selling Plus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data PSTV Institutional Buying and Selling by Quarter Remove Ads Plus Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/7/2024AIGH Capital Management LLC568,681$836K0.3%N/A9.977% 11/15/2022Parkman Healthcare Partners LLC1,325,025$590K0.2%-13.6%3.943% 8/8/2022Otter Creek Advisors LLC330,168$178K0.1%+293.5%1.465% 5/13/2022Parkman Healthcare Partners LLC1,526,316$1.53M0.4%N/A6.875% 5/9/2022Otter Creek Advisors LLC83,901$84K0.0%N/A0.378% 11/9/2021BlackRock Inc.128,323$245K0.0%-19.7%0.835% 9/17/2021Virtu Financial LLC76,187$195K0.0%N/A0.630% 8/16/2021State Street Corp34,214$88K0.0%N/A0.283% 8/13/2021Renaissance Technologies LLC17,607$45K0.0%N/A0.146% 8/13/2021Northern Trust Corp40,524$104K0.0%N/A0.335% 8/13/2021Geode Capital Management LLC130,793$334K0.0%N/A1.082% 8/13/2021Vanguard Group Inc.712,847$1.83M0.0%+824.7%5.897% 8/12/2021Dimensional Fund Advisors LP68,430$175K0.0%N/A0.566% 8/11/2021Susquehanna Fundamental Investments LLC13,033$33K0.0%N/A0.108% 2/24/2021Virtu Financial LLC18,318$37K0.0%-16.5%0.383% (Data available from 1/1/2016 forward)Remove Ads PSTV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PSTV shares? During the previous two years, the following institutional investors and hedge funds held shares of Plus Therapeutics shares: AIGH Capital Management LLC ($836K).Learn more on PSTV's institutional investors. What percentage of Plus Therapeutics stock is owned by institutional investors? 3.28% of Plus Therapeutics stock is owned by institutional investors. Learn more on PSTV's institutional investor holdings. Which institutional investors have been buying Plus Therapeutics stock? The following institutional investors have purchased Plus Therapeutics stock in the last 24 months: AIGH Capital Management LLC ($568.68K). How much institutional buying is happening at Plus Therapeutics? Institutional investors have bought a total of 568,681 shares in the last 24 months. This purchase volume represents approximately $835.96K in transactions. Related Companies Beyond Air Institutional Ownership QT Imaging Institutional Ownership Vivos Therapeutics Institutional Ownership ReWalk Robotics Institutional Ownership IRIDEX Institutional Ownership NeuroOne Medical Technologies Institutional Ownership Allurion Technologies Institutional Ownership NeurAxis Institutional Ownership SeaStar Medical Institutional Ownership STRATA Skin Sciences Institutional Ownership This page (NASDAQ:PSTV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
